HITIQ Limited (ASX:HIQ) Converts $1.6m Notes to Shares and Secures New Advisory Mandate
HITIQ Limited (ASX:HIQ) converts $1.6m in notes into shares and secures a new advisory mandate to enhance US investor relations.
Chimeric Therapeutics Limited (ASX:CHM) Reports Q4 Activities
Chimeric Therapeutics (ASX:CHM) advances clinical trials, secures $5M in funding, and appoints Dr Rebecca McQualter as CEO in Q4 report.
Audio Pixels Holdings Limited (ASX:AKP) Advances Operations and Issues $2M Convertible Notes Amid ASX Suspension
Audio Pixels Holdings (ASX:AKP) reports progress on digital sound technologies, issues $2M in convertible notes, and updates on ASX suspension status.
Marquee Resources (ASX:MQR) Releases Q4 2024 Activities Report
Marquee Resources (ASX:MQR) reports significant exploration progress and strong financial updates in its Q4 2024 Activities Report.
Structural Monitoring Systems Plc (ASX:SMN) Secures $8.7M Capital Raise and Achieves $2M Sales Growth
Structural Monitoring Systems Plc (ASX:SMN) secures $8.7M in capital and boosts sales by $2M, signaling strong growth and financial stability.
Terra Metals Limited (ASX:TM1) Reports High-Grade Drill Results and Expands Dante Project
Terra Metals Limited (ASX:TM1) reports high-grade drill results at Dante Project and secures options for additional tenements, enhancing its mineral portfolio.
Arovella Therapeutics Limited (ASX:ALA) Raises $20M to Fund Phase 1 Clinical Trials
Arovella Therapeutics (ASX:ALA) secures $20 million placement, fully funding Phase 1 trials for ALA-101 and advancing its cancer therapy pipeline.
Blue Energy Limited (ASX:BLU) Releases Q4 2024 Quarterly Activities Report
Blue Energy Limited (ASX:BLU) releases Q4 2024 report highlighting ongoing production testing, financial stability, and progress in legal and exploration activities.
Dotz Nano Ltd (ASX:DTZ) Secures First US Commercial Order and A$2M Investment
Dotz Nano Ltd (ASX:DTZ) secures its first US commercial order for DotzShield and receives a further A$2M investment to advance carbon capture technologies.
Vectus Biosystems Limited (ASX:VBS) Releases December 2024 Quarterly Activities Report
Vectus Biosystems Limited (ASX:VBS) releases its December 2024 Quarterly Activities Report, detailing clinical trial progress and a strong financial position.